COMMUNIQUÉS West-GlobeNewswire
-
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
29/07/2026 -
Alira Health Establishes Annabel de Maria Memorial Scholarship to Inspire the Next Generation of Healthcare Leaders
29/07/2026 -
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
29/07/2026 -
Solésence To Report Second Quarter 2026 Financial Results and Host a Conference Call on August 11
28/07/2026 -
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026
28/07/2026 -
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28/07/2026 -
Scientists Turn COVID-19 Immune Memory into a Powerful New Ally Against Cancer
28/07/2026 -
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07/2026 -
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
28/07/2026 -
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
28/07/2026 -
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
28/07/2026 -
Chemed Reports Second-Quarter 2026 Results
28/07/2026 -
Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness
28/07/2026 -
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
28/07/2026 -
PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
28/07/2026 -
Medical Grade Physiotherapy & Wellness Brings Extensive Experience to WSIB and MVA Physiotherapy Care in Burlington, Ontario
29/07/2026 -
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
28/07/2026 -
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07/2026 -
CancerVax Named a Top Preclinical Biotech Company of 2026 by Life Sciences Review
28/07/2026
Pages